CN118175993A - 一种抗sost抗体药物组合物及其用途 - Google Patents

一种抗sost抗体药物组合物及其用途 Download PDF

Info

Publication number
CN118175993A
CN118175993A CN202280072603.5A CN202280072603A CN118175993A CN 118175993 A CN118175993 A CN 118175993A CN 202280072603 A CN202280072603 A CN 202280072603A CN 118175993 A CN118175993 A CN 118175993A
Authority
CN
China
Prior art keywords
pharmaceutical composition
seq
antibody
concentration
sost
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280072603.5A
Other languages
English (en)
Chinese (zh)
Inventor
单爽
田晨敏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN118175993A publication Critical patent/CN118175993A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN202280072603.5A 2021-11-30 2022-11-30 一种抗sost抗体药物组合物及其用途 Pending CN118175993A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111462784 2021-11-30
CN2021114627846 2021-11-30
PCT/CN2022/135247 WO2023098694A1 (zh) 2021-11-30 2022-11-30 一种抗sost抗体药物组合物及其用途

Publications (1)

Publication Number Publication Date
CN118175993A true CN118175993A (zh) 2024-06-11

Family

ID=86611532

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280072603.5A Pending CN118175993A (zh) 2021-11-30 2022-11-30 一种抗sost抗体药物组合物及其用途

Country Status (8)

Country Link
US (1) US20250011411A1 (enExample)
EP (1) EP4434517A4 (enExample)
JP (1) JP2024543931A (enExample)
CN (1) CN118175993A (enExample)
AU (1) AU2022401939A1 (enExample)
CA (1) CA3238868A1 (enExample)
TW (1) TW202330032A (enExample)
WO (1) WO2023098694A1 (enExample)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2011126338A (ru) * 2008-11-28 2013-01-10 Эбботт Лэборетриз Стабильные композиции антител и способы их стабилизации
AR075715A1 (es) * 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado
GB201112429D0 (en) * 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
HK1200322A1 (en) * 2011-10-24 2015-08-07 Abbvie Inc. Immunobinders directed against sclerostin
SI3269735T1 (sl) 2015-03-13 2020-12-31 Jiangsu Hengrui Medicine Co. Ltd. Protitelo proti sklerostinu, antigen-vezavni fragment in medicinska uporaba le-tega
GB201604124D0 (en) * 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
CN109952093B (zh) 2017-07-27 2022-02-08 江苏恒瑞医药股份有限公司 一种sost抗体药物组合物及其用途
EP4013786A1 (en) * 2019-08-12 2022-06-22 Amgen Inc. Anti-sclerostin antibody formulations

Also Published As

Publication number Publication date
AU2022401939A1 (en) 2024-05-30
TW202330032A (zh) 2023-08-01
WO2023098694A1 (zh) 2023-06-08
US20250011411A1 (en) 2025-01-09
EP4434517A1 (en) 2024-09-25
EP4434517A4 (en) 2025-06-25
JP2024543931A (ja) 2024-11-26
CA3238868A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
RU2690850C2 (ru) Составы на основе биспецифических антител к il-4/il-13
EP2844286B1 (en) Lyophilised and aqueous anti-cd40 antibody formulations
CN109952093B (zh) 一种sost抗体药物组合物及其用途
EP3714901A1 (en) Lag-3 antibody pharmaceutical composition and use thereof
JP2023501377A (ja) 高濃度抗ｃ５抗体配合物
CN110732023A (zh) 一种her2抗体药物组合物及其用途
CN110960490A (zh) 一种抗egfr抗体偶联药物组合物及其用途
WO2020200099A1 (zh) 包含抗il-5抗体的药物组合物及其用途
JP2018531980A (ja) 抗ｄ因子抗体製剤
WO2022117060A1 (zh) 一种含抗结缔组织生长因子抗体的药物组合物
CN118175993A (zh) 一种抗sost抗体药物组合物及其用途
CN114786717B (zh) 稳定的水性抗-tfpi抗体制剂
CN115227813A (zh) 一种含抗Abeta抗体的药物组合物
HK40009387B (en) Sost antibody pharmaceutical composition and uses thereof
HK40009387A (en) Sost antibody pharmaceutical composition and uses thereof
TW202333789A (zh) 一種包含抗ＦＸＩ／ＦＸＩａ抗體的醫藥組成物及其用途
CN118078988A (zh) 包含靶向il-17a的抗体药物组合物
TW202541841A (zh) 用於治療ｃ１ｓ介導病症的包含抗體的醫藥組成物及其使用方法
WO2025094976A1 (ja) ヘモジデリンの沈着及び／又は滑膜肥厚の改善又は抑制剤
CN120437287A (zh) 一种包含特异性结合gucy2c和cd3的双特异性抗体的药物组合物
HK40075201B (zh) 稳定的水性抗-tfpi抗体制剂
HK40075201A (en) Stable aqueous anti-tfpi antibody formulation
HK40059623A (en) Pharmaceutical composition containing antibody against il-5 and use thereof
HK40023281A (en) Lyophilised and aqueous anti-cd40 antibody formulations
HK1202050B (en) Lyophilised and aqueous anti-cd40 antibody formulations

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40112460

Country of ref document: HK